Immunobiology: Receptors and signaling in mast cells. Implications in pathology. PI: Margarita Martín Andorrà

Presentation

Our group is interested in the regulation of the immune system by receptors of the CD150 and CD300 family members and adapter molecules related to these families.

In the last years we have focus mainly in the regulatory role of mast cells in innate and adaptative immunity. Mast cells are currently recognized as effector cells in many settings other than mere allergic reactions, including innate immunity, autoimmunity, chronic inflammatory disorders and atherosclerosis. The classic and most studied activation pathway of these cells starts with the binding of IgE to the high-affinity Fc receptor for IgE (FcepsilonRI); and the release of histamine and other mediators after crosslinking of surface-bound IgE by allergen. Appropriate activation and fine tunning of mast cell responses is mediated by a complex array of factors including IgE receptor, kinases/phosphatases, adaptor molecules, and various classes of co-stimulatory molecules that modulate their function. These molecules may therefore contribute to the outcome of mast cell-associated pathologies, and may constitute new therapeutic targets in such diseases.

For further details of our activities please consult our website: http://www.idibaps.org/recerca/605/immunoal%C2%B7lergia-respiratoria-clinica-i-experimental-irce

KEYWORDS: Mast cell receptors, Signal transduction, Innate immunity, Mast cell-related disorders, KIT oncogenic diseases

 

Margarita Martín-Andorrà
PhD
martin_andorra@ub.edu

Eva Serrano-Candelas
PhD
eva.serrano.candelas@gmail.com

Mario Guerrero Grueso
Technician
mguerrero@ub.edu

Yanru Guo
Doctorate student
guoyanru09@hotmail.com

Elizabeth Proaño Pérez
Doctorate student
elizabethproaño@gmail.com

Laia Ollé  Boix
Predoctoral researcher
laia.olle@hotmail.com

Cristina Font Miñarro
TFG student
crfontmi7@alumnes.ub.edu

  • Study of mast cell receptors. Implications in pathology.
  • Molecular mechanisms in IgE-dependent and independent anaphylaxis.
  • Regulation of the oncogenic KIT receptor in mastocytosis and gastrointestinal stromal tumors (GIST).
  • Study of inhibitory receptors of the CD300 family and their role in innate immunity.

  • Identificación de dianas terapéuticas y biomarcadores genéticos de gravedad en la anafilaxia

Entity: Hospital Clínic, Barcelona
PI: Rosa M Muñoz Cano (Investigadora col.laboradora Margarita Martín Andorrà)
Funding entity: Fundación de la Sociedad Española de Alergología e Inmunología Clínica (SEAIC)
Funding entity code:SEAIC1920_B01
Dates: Setembre 2020-Setembre 2023
Amount: 50.000 €

  • Estudio de nuevos mecanismos en la activación mastocitaria y la supervivencia celular. Implicaciones en patologias con KIT oncogénico y en reacciones anafilácticas

Entity: Universitat de Barcelona
PI: Margarita Martín Andorrà
Funding entity: Ministerio de Economia y Competitividad
Funding entity code: RTI2018-096915-B-I00
Dates: 2019-2021
Amount: 163.350 €

  • Asma, Reacciones Adversas y Alérgicas (ARADYAL)

Entity: IDIBAPS
PI: Joan Bartra Tomás
Funding entity: Ministerio de Economia y Competitividad. Redes Temáticas de Investigación Corporativa
Funding entity code: RD16/0006/0007
Dates: 2017-2021
Amount: 101.750 €

  • Regulación de la expresión y función de KIT y PDGFRalfa por la molécula adaptadora 3BP2. Implicación en la diferenciación y migración mastocitaria y en patología.

Entity: Universitat de Barcelona
PI: Margarita Martín Andorrà
Funding entity: Ministerio de Economia y Competitividad
Funding entity code: SAF2015-68124-R
Dates: 2016-2018
Amount: 157.300 €

  • Study of Omalizumab's mechanism of action in Chronic Urticaria (CU)

Entity: Fundació Clínic per a la Recerca Biomèdica/ Universitat Clínica de Navarra/ Universitat de Barcelona.
PI: Marta Ferrer
Funding entity: Novartis Farmacéutica, S.A
Dates: 2013-2017
Amount: 220.000 €

For more information for PI publications click in the link:
ORCID: https://orcid.org/0000-0002-9245-4899
ResearcherID: http://www.researcherid.com/rid/H-2025-2015

 

Proaño-Pérez Elizabeth; Serrano-Candelas Eva; García-Valverde Alfonso; Rosell Jordi; Gómez-Peregrina David; Navinés-Ferrer Arnau; Guerrero Mario; Serrano César; Martín Margarita. The microphthalmia-associated transcription factor is involved in gastrointestinal stromal tumor growth. Cancer Gene Ther. 2022 Oct 14. doi: 10.1038/ s41417-022-00539-1. Online ahead of print. PMID: 36241703

Torres-Atencio I, Campble A, Goodridge A, Martin M. Uncovering the Mast Cell Response to Mycobacterium tuberculosis. Front Immunol. 2022 Jun 2;13:886044. doi: 10.3389/ fimmu.2022.886044. eCollection 2022. PMID: 35720353

Martin M. Mast Cells: When the Best Defense Is an Attack? Int J Mol Sci. 2022 Mar 25;23(7): 3570. doi: 10.3390/ ijms23073570. PMID: 35408929

Garcia-Garcia, L.; Olle, L.; Martin, M.; Roca-Ferrer, J.; Muñoz-Cano, R. Adenosine Signaling in Mast Cells and Allergic Diseases. Int. J. Mol. Sci. 2021, 22(10), 5203. Published: 14 May 2021.

Guo, Y.; Proaño-Pérez, E.; Muñoz-Cano, R.; Martin, M. Anaphylaxis: Focus on Transcription Factor Activity. Int. J. Mol. Sci. 2021, 22(9), 4935. Published: 6 May 2021.

Ribó P, Guo Y, Aranda J, Ainsua-Enrich E, Navinés-Ferrer A, Guerrero M, Pascal M, de la Cruz C, Orozco M, Muñoz-Cano R, Martin M. Mutation in KARS: A novel mechanism for severe anaphylaxis. J Allergy Clin Immunol. 2021 May; 147(5):1855-1864.e9. doi: 10.1016/ j.jaci.2020.12.637. PMID: 33385443.

Navinés-Ferrer A, Ainsua-Enrich E, Serrano-Candelas E, Proaño-Pérez E, Muñoz-Cano R, Gastaminza G, Olivera A, Martin M. MYO1F Regulates IgE and MRGPRX2-Dependent Mast Cell Exocytosis. J Immunol. 2021 May 15; 206(10): 2277-2289. doi: 10.4049/ jimmunol. 2001211. Epub 2021 May 3. PMID: 33941653.

Quan PL, Sabaté-Brescó M, Guo Y, Martín M, Gastaminza G. The Multifaceted Mas-Related G Protein-Coupled Receptor Member X2 in Allergic Diseases and Beyond. Int J Mol Sci. 2021 Apr 23; 22(9): 4421. doi: 10.3390/ ijms 22094421. PMID: 33922606.

Muñoz-Cano R, San Bartolome C, Casas-Saucedo R, Araujo G, Gelis S, Ruano-Zaragoza M, Roca-Ferrer J, Palomares F, Martin M, Bartra J, Pascal M. Immune-Mediated Mechanisms in Cofactor-Dependent Food Allergy and Anaphylaxis: Effect of Cofactors in Basophils and Mast Cells. Front Immunol. 2021 Feb 17; 11:623071. doi: 10.3389/ fimmu. 2020.623071. PMID: 33679712.

Muñoz-Cano RM, Casas R, Araujo G, de la Cruz C, Martin M, Roca-Ferrer J, Perez M, Torradeflot M, San Bartolome C, Picado C, Bartra J, Pascal M. Prostaglandin E2 decreases basophil activation in patients with food-induced anaphylaxis. Allergy. 2021 May; 76(5): 1556-1559. doi: 10.1111/ all.14615. Epub 2020 Oct 21. PMID: 33029821.

Navinés-Ferrer A, Martín M.Tailed Unconventional Class I Myosins in Health and Disease. Int J Mol Sci. 2020 Apr 7;21(7): 2555. doi: 10.3390/ ijms21072555. PMID: 3227264

Nadine Landolina, Ilan Zaffran, Dubravka Smiljkovi , Eva Serrano-Candelas, Dominik Schmiedel, Sheli Friedman, Michel Arock, Karin Hartmann, Eli Pikarsky, Ofer Mandelboim, Margarita Marti , Peter Valent, Francesca Levi-Schaffer. Activation of Siglec-7 Results in Inhibition of in Vitro and in Vivo Growth of Human Mast Cell Leukemia Cel. Pharmacol Res. 2020 Feb 5;104682. doi: 10.1016/ j.phrs.2020.104682. PMID: 32035162

Navinés-Ferrer A, Ainsua-Enrich E, Serrano-Candelas E, Sayós J, Martin M. Myo1f, an Unconventional Long-Tailed Myosin, Is a New Partner for the Adaptor 3BP2 Involved in Mast Cell Migration.Front Immunol. 2019 May 9; 10: 1058. doi: 10.3389/ fimmu. 2019. 01058. eCollection 2019. PMID: 6521229

Navinés-Ferrer A, Serrano-Candelas E, Lafuente A, Muñoz-Cano R, Martín M*, Gastaminza G*. MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia.Sci Rep. 2018 Aug 2; 8(1): 11628. doi: 10. 1038/ s41598-018- 29965-8. PMID: 30072729 *Co-corresponding and last author 

Serrano-Candelas E, Ainsua-Enrich E, Navinés-Ferrer A, Rodrigues P, García-Valverde A, Bazzocco S, Macaya I, Arribas J, Serrano C, Sayós J, Arango D, Martin M. Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.Mol Oncol. 2018 Aug;12 (8): 1383-1397. doi: 10.1002/ 1878-0261. 12332. Epub 2018 Jun 30. PMID: 29885053.

Martínez-Barriocanal Á, Arcas-García A, Magallon-Lorenz M, Ejarque-Ortíz A, Negro-Demontel ML, Comas-Casellas E, Schwartz S Jr, Malhotra S, Montalban X, Peluffo H, Martín M, Comabella M, Sayós J. Effect of Specific Mutations in Cd300 Complexes Formation; Potential Implication of Cd300f in Multiple Sclerosis. Sci Rep. 2017 Oct 19;7(1): 13544. doi: 10.1038/ s41598-017-12881-8. PMID: 29051512

Serrano-Candelas E, Martínez-Aranguren R, Vega O, Gastaminza G, Bartra J, Audicana MT, Núñez-Córdoba JM, Algorta J, Valero A, Martin M*, Ferrer M. Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells. Sci Rep. 2017 Aug 21;7(1): 8985. doi: 10. 1038/ s41598-017- 09361-4. PMID: 28827590.  *Co-corresponding and last author 

Navinés-Ferrer A, Serrano-Candelas E, Molina-Molina GJ, Martín M. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments. J Immunol Res. 2016; 2016: 8163803. doi: 10.1155/ 2016/8163803. Epub 2016 Dec 21. Review. PMID: 28097159.

Munoz-Cano R, Ainsua-Enrich E, Torres-Atencio I, Martin M, Sánchez-Lopez J, Bartra J, Picado C, Mullol J, Valero A. Effects of Rupatadine on Platelet- Activating Factor-Induced Human Mast Cell Degranulation Compared With Desloratadine and Levocetirizine (The MASPAF Study). J Investig Allergol Clin Immunol. 2017; 27(3):161-168. doi: 10.18176/ jiaci.0117. Epub 2016 Oct 19. PMID: 27758758.

Serrano-Candelas E, Martinez-Aranguren R, Valero A, Bartra J, Gastaminza G, Goikoetxea MJ, Martín M*, Ferrer M*. Comparable actions of omalizumab on mast cells and basophils. Clin Exp Allergy. 2016 Jan;46(1): 92-102. doi: 10.1111/ cea.12668. *Co-corresponding and last author 

Machado-Carvalho L, Martín M, Torres R, Gabasa M, Alobid I, Mullol J, Pujols L, Roca-Ferrer J,Picado C. Low E-prostanoid 2 receptor levels and deficient induction of the IL-1ß/IL-1 type I receptor/COX-2 pathway: Vicious circle in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016 Jan;137(1): 99-107.e7. doi: 10.1016/ j.jaci.2015. 09.028. PMID: 26560040

Ejarque-Ortiz A, Solà C, Martínez-Barriocanal Á, Schwartz S Jr, Martín M, Peluffo H, Sayós J. The Receptor CMRF35-Like Molecule-1 (CLM-1) Enhances the Production of LPS-Induced Pro-Inflammatory Mediators during Microglial Activation. PLoS One. 2015 Apr 30;10(4): e0123928. doi: 10.1371/ journal.pone.0123928. eCollection 2015. PMID: 25927603

Ainsua-Enrich E, Serrano-Candelas E, Álvarez-Errico D, Picado C, Sayós J, Rivera J, Martín M. The adaptor 3BP2 is required for KIT receptor expression and human mast cell survival. J Immunol. 2015 May 1;194(9):4309-18. PMID: 25810396

Torres-Atencio I, Ainsua-Enrich E, de Mora F, Picado C, Martín M. Prostaglandin E2 prevents hyperosmolar-induced human mast cell activation through prostanoid receptors EP2 and EP4. PLoS One. 2014 Oct 20; 9(10): e110870. doi: 10.1371/ journal.pone.0110870. eCollection 2014. PMID: 25329458

Ainsua-Enrich E, Alvarez-Errico D, Gilfillan AM, Picado C, Sayós J, Rivera J, Martín M. The adaptor 3BP2 is required for early and late events in FcεRI signaling in human mast cells. J Immunol. 2012 Sep 15; 189(6): 2727-34. doi: 10.4049/ jimmunol. 1200380. Epub 2012 Aug 15. PMID: 22896635

Comas-Casellas E, Martínez-Barriocanal Á, Miró F, Ejarque-Ortiz A, Schwartz S Jr, Martín M, Sayós J. Cloning and characterization of CD300d, a novel member of the human CD300 family of immune receptors. J Biol Chem. 2012 Mar 23; 287 (13): 9682-93. Epub 2012 Jan 30. PMID: 22291008

  • Offers from the University of Barcelona:

Work UB

  • Offers from the Research Group:

At the moment, there are no job offers from this Research Group

Share:
Facebook
Twitter
LinkedIn
Email